Text Size

Thai Cancer Anemia Survey in Chulalongkorn Hospital

This study has been completed.
Sponsor:
Information provided by:
Janssen-Cilag Ltd.,Thailand
ClinicalTrials.gov Identifier:
NCT01018043
First received: November 19, 2009
Last updated: March 11, 2010
Last verified: March 2010
History of Changes
  Purpose

The purpose of this study is to create a large Thailand database documenting the severity of anemia and its management in the cancer population.


Condition Intervention
Anemia
Cancer
 Other: Adult Cancer Patients

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Thai Cancer Anemia Survey in Chulalongkorn Hospital

Resource links provided by NLM:

MedlinePlus related topics: Anemia Cancer
U.S. FDA Resources

Further study details as provided by Janssen-Cilag Ltd.,Thailand:

Primary Outcome Measures:
  • Number of patients that have anemia during cancer therapy [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Characteristic of each patients example treatment duration,type and chemotherapy using, grade of anemia [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Enrollment: 264
Study Start Date: April 2006
Study Completion Date: December 2009
Groups/Cohorts Assigned Interventions
001
Adult Cancer Patients Tracking anemia management in Adult Cancer Patients
 Other: Adult Cancer Patients
Tracking anemia management in Adult Cancer Patients

Detailed Description:

Thai Cancer Anemia Study (TCAS) is a prospective survey that will track anemia management in an adult cancer population. This survey is not intended to interfere with standard medical practices for handling anemia. Information on laboratory values including target and achieved hemoglobin (Hb) levels during chemotherapy cycles, use of blood transfusions, iron supplementation, and epoetin will be collected in addition to information on cancer status and treatment. Data on the level that triggers clinicians to decide on the need for anemia therapy will also be collected. Each patient included in the survey will be followed for six months. Observational Study - No investigational drug administered

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Anemic patients with cancer receiving chemotherapy

Criteria

Inclusion Criteria:

  • Patients with cancer

Exclusion Criteria:

  • None
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01018043

Sponsors and Collaborators
Janssen-Cilag Ltd.,Thailand
Investigators
Study Director: Janssen-Cilag Ltd Clinical Trial Janssen-Cilag Ltd.
  More Information

No publications provided

Responsible Party: Medical Affairs Director, Janssen-Cilag Ltd.,Thailand
ClinicalTrials.gov Identifier: NCT01018043     History of Changes
Other Study ID Numbers: CR011731, TCAS-CU-ONCO-2006
Study First Received: November 19, 2009
Last Updated: March 11, 2010
Health Authority: Thailand: Ministry of Public Health

Keywords provided by Janssen-Cilag Ltd.,Thailand:
Cancer Anemia Survey
Chulalongkorn hospital

Additional relevant MeSH terms:
Anemia
Hematologic Diseases

ClinicalTrials.gov processed this record on May 16, 2013